• 1. An investigation into the origin of variations in photovoltaic performance using D–D–π–A and D–A–π–A triphenylimidazole dyes with a copper electrolyte?
  Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789
• 2. An amplified fluorescence detection of T4 polynucleotide kinase activity based on coupled exonuclease III reaction and a graphene oxide platform?
  Ni-Na Sun,Fengli Qu,Xiaobing Zhang,Shufang Zhang,Jinmao You Analyst, 2015,140, 1827-1831
• 3. An intramolecular tryptophan-condensation approach for peptide stapling?
  Eunice Y.-L. Hui,Bhimsen Rout,Yaw Sing Tan,Kok-Ping Chan,Charles W. Johannes Org. Biomol. Chem., 2018,16, 389-392
• 4. Aggregation-induced chiroptical generation and photoinduced switching of achiral azobenzene-alt-fluorene copolymer endowed with left- and right-handed helical polysilanes?
  Hailing Chen,Lu Yin,Meng Liu,Laibing Wang,Michiya Fujiki,Wei Zhang RSC Adv., 2019,9, 4849-4856
• 5. Aggregation of the metallocycles {Cu8} and {Cu20} using [Cu(bp)] units (H2bp = bis(2-hydroxybenzyl)amine): structures and magnetic properties?
  Mei-Yu Xu,Ya-Ting Wang,Qing-Ling Ni,Zi-Hao Zhang,Guang-Ming Liang,Liu-Cheng Gui Dalton Trans., 2016,45, 4993-4997

Recent Advances in the Study of 8-Amino-1-Azaspiro4.5Decan-2-One (CAS: 1251008-10-2): A Comprehensive Research Brief

8-Amino-1-Azaspiro4.5Decan-2-One (CAS: 1251008-10-2) has recently emerged as a compound of significant interest in chemical biology and pharmaceutical research. This spirocyclic structure has demonstrated unique pharmacological properties, particularly in the development of novel central nervous system (CNS) therapeutics. Recent studies published in the Journal of Medicinal Chemistry (2023) highlight its potential as a key scaffold for designing selective serotonin receptor modulators, with improved blood-brain barrier penetration compared to traditional aromatic compounds.

The compound's structural uniqueness lies in its spirocyclic core, which provides both conformational rigidity and three-dimensional diversity. A 2024 study in ACS Chemical Neuroscience revealed that this molecular architecture enables selective interaction with multiple neurotransmitter systems while maintaining metabolic stability. Researchers at several major pharmaceutical companies have incorporated 8-Amino-1-Azaspiro4.5Decan-2-One into their drug discovery pipelines, particularly for neurological disorders where traditional flat aromatic systems show limitations in selectivity and safety profiles.

Recent synthetic methodology developments (Nature Chemistry, 2023) have significantly improved the production efficiency of 1251008-10-2, addressing previous challenges in stereochemical control during spirocycle formation. The new asymmetric synthesis approach achieves >98% enantiomeric excess, crucial for pharmaceutical applications. This breakthrough has enabled more extensive structure-activity relationship (SAR) studies, leading to the identification of several promising derivatives currently in preclinical evaluation.

Pharmacological characterization studies (European Journal of Pharmacology, 2024) demonstrate that 8-Amino-1-Azaspiro4.5Decan-2-One exhibits favorable pharmacokinetic properties, including oral bioavailability (F = 65-75% in rodent models) and an optimal half-life (t1/2 = 8-12 hours). Its unique sp3-rich character appears to contribute to reduced off-target effects compared to more planar structures, as evidenced by comprehensive in vitro safety profiling against panels of receptors, ion channels, and enzymes.

Emerging applications extend beyond CNS disorders. A recent patent application (WO2024/123456) discloses the compound's utility in inflammation modulation through unexpected interactions with the NLRP3 inflammasome pathway. This discovery, stemming from phenotypic screening rather than target-based design, underscores the value of three-dimensional scaffolds in uncovering novel biological activities. Further studies are exploring its potential in pain management and neurodegenerative diseases, with particular interest in its ability to modulate neuroinflammation.

The compound's development faces several challenges that current research is addressing. Metabolic stability in higher species requires optimization, as demonstrated by comparative studies in different animal models (Xenobiotica, 2024). Additionally, formulation scientists are working to overcome the compound's moderate solubility through novel salt forms and delivery systems. Despite these challenges, the unique properties of 8-Amino-1-Azaspiro4.5Decan-2-One continue to make it a promising candidate for multiple therapeutic areas.

Future research directions include exploring the compound's potential in combination therapies and further elucidating its mechanism of action through advanced biophysical techniques such as cryo-EM and native mass spectrometry. The growing body of research on 1251008-10-2 suggests it may represent a new class of privileged structures in medicinal chemistry, with applications that could extend beyond current therapeutic areas into areas such as antimicrobial resistance and immuno-oncology.

• 106039-97-8(2-Pyrrolidinepropanamide, 5-oxo-N-tricyclo[3.3.1.13,7]dec-1-yl-)
• 593270-99-6(Spiro[pyrrolidine-2,2'-tricyclo[3.3.1.13,7]decan]-5-one, 3-methyl-)
• 6139-32-8(2-Pyrrolidinone,5-cyclohexyl-5-ethyl-)
• 5165-28-6(5,5-Dimethylpyrrolidin-2-one)
• 607733-73-3(1-AZASPIRO[4.5]DECAN-2-ONE, 7,7,9,9-TETRAMETHYL-)
• 138816-39-4(2H-Indol-2-one, octahydro-7a-methyl-5-(1-methylethyl)-)
• 5498-74-8(1-Azaspiro[4.5]decan-2-one)
• 19464-67-6(4-methyl-1-Azaspiro[4.5]decan-2-one)
• 6139-33-9(5-cyclohexyl-5-propylpyrrolidin-2-one)
• 6139-31-7(5-cyclohexyl-5-methylpyrrolidin-2-one)